1.
Gynecol Oncol Rep
; 29: 70-72, 2019 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31360743
RESUMO
â¢Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies.â¢Targetable mutations may lead to new therapies in gynecologic cancer treatment.â¢Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 inhibitors.â¢Afatinib shows promising response rates in lung cancers carrying Her2/neu mutations.â¢Afatinib may be effective in serous ovarian tumors exhibiting Her2/neu or ERBB2 mutations.